Literature DB >> 7234873

The effect of continuous normalization of serum hemolytic complement on the course of lupus nephritis: a five year prospective study.

M P Jarrett, L B Sablay, L Walter, P Barland, A I Grayzel.   

Abstract

We have completed a five year prospective study of the effect of continuous normalization of serum hemolytic complement (CH50) in 25 patients with lupus nephritis. At the end of five years 22 patients were being actively followed; 13 in a CH50 controlled group and nine in a CH50 uncontrolled group. Serial renal biopsy specimens were obtained from 19 patients. The results demonstrate a trend toward stabilization of renal histology, creatinine clearance and serum creatinine at a lower final mean dose of prednisone in the complement controlled group.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7234873     DOI: 10.1016/0002-9343(81)90870-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  New approaches to treating systemic lupus erythematosus.

Authors:  D Wofsy
Journal:  West J Med       Date:  1987-08

2.  Complement depletion accelerates the clearance of immune complexes from the circulation of primates.

Authors:  F J Waxman; L A Hebert; J B Cornacoff; M E VanAman; W L Smead; E H Kraut; D J Birmingham; J M Taguiam
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

3.  Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis.

Authors:  E H Garin; J W Sleasman; G A Richard; A A Iravani; R S Fennell
Journal:  Eur J Pediatr       Date:  1986-10       Impact factor: 3.183

4.  The double edged sword of the immune response: mutational analysis of a murine anti-pneumococcal, anti-DNA antibody.

Authors:  C Putterman; W Limpanasithikul; M Edelman; B Diamond
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

5.  Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus.

Authors:  E H Cole; J Schulman; M Urowitz; E Keystone; C Williams; G A Levy
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.